Tremelimumab + Durvalumab

Phase 2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

EGFR Mutant Advanced Non Small Cell Lung Cancer

Conditions

EGFR Mutant Advanced Non Small Cell Lung Cancer

Trial Timeline

Oct 23, 2018 → Jan 31, 2024

NCT ID

NCT03994393

About Tremelimumab + Durvalumab

Tremelimumab + Durvalumab is a phase 2 stage product being developed by AstraZeneca for EGFR Mutant Advanced Non Small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT03994393. Target conditions include EGFR Mutant Advanced Non Small Cell Lung Cancer.

What happened to similar drugs?

1 of 7 similar drugs in EGFR Mutant Advanced Non Small Cell Lung Cancer were approved

Approved (1) Terminated (1) Active (5)

🔄AZD9291 + MEDI4736AstraZenecaPhase 3

🔄AZD9291 80mg oral each dayAstraZenecaPhase 3

✅GefitinibAstraZenecaApproved

🔄AZD9291 80 mg/40 mg + placebo + Placebo Erlotinib 150/100mg + Placebo Gefitinib 250 mg + Erlotinib 150/100 mg + Gefitinib 250 mg + Placebo AZD9291 80 mg/ 40 mgAstraZenecaPhase 3

🔄Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)MerckPhase 3

❌ERLOTINIB WITH CHEMOTHERAPY + CHEMOTHERAPY ONLYRochePhase 3

🔄Dacomitinib (PF-00299804) + GefitinibPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06526104	Phase 2	Recruiting	Dec 2, 2024	Dec 1, 2027	Hepatocellular Carcinoma
NCT04522544	Phase 2	Recruiting	Dec 15, 2020	Dec 31, 2027	Hepatocellular Carcinoma Non-resectable
NCT03994393	Phase 2	UNKNOWN	Oct 23, 2018	Jan 31, 2024	EGFR Mutant Advanced Non Small Cell Lung Cancer
NCT03482102	Phase 2	Recruiting	May 14, 2018	Oct 1, 2026	Hepatocellular Carcinoma
NCT03075527	Phase 2	Terminated	Apr 10, 2017	Dec 16, 2024	Mesothelioma
NCT02870920	Phase 2	Completed	Oct 12, 2016	Jun 7, 2022	Colorectal Cancer

Competing Products

20 competing products in EGFR Mutant Advanced Non Small Cell Lung Cancer

See all competitors

Product	Company	Stage	Hype Score
YH25448	Yuhan	Phase 1/2	32
YH32364	Yuhan	Phase 1/2	39
Datopotamab deruxtecan	Daiichi Sankyo	Pre-clinical	26
HER3-DXd	Daiichi Sankyo	Pre-clinical	26
ASP8273	Astellas Pharma	Phase 2	27
radio-labeled naquotinib + naquotinib	Astellas Pharma	Phase 1	21
erlotinib	Astellas Pharma	Phase 1	29
ASP8273 Capsules + ASP8273 Capsules A	Astellas Pharma	Phase 2	27
famitinib po + HS-10296 po	Jiangsu Hengrui Medicine	Phase 2	31
ABT-414	AbbVie	Pre-clinical	26
AZD9291 40 mg + AZD9291 80 mg	AstraZeneca	Phase 1	29
Osimertinib-based adaptive treatment + Osimertinib 80 MG	AstraZeneca	Phase 2	42
AZD9291 + MEDI4736	AstraZeneca	Phase 3	40
EGFR TKIs (gefitinib, erlotinib, afatinib, et al)	AstraZeneca	Pre-clinical	22
AZD9291	AstraZeneca	Pre-clinical	26
Osimertinib	AstraZeneca	Phase 2	35
Dasatinib + Osimertinib	AstraZeneca	Phase 1/2	24
AZD9291 80mg oral each day	AstraZeneca	Phase 3	36
Osimertinib	AstraZeneca	Phase 2	35
AZD3759 + AZD9291	AstraZeneca	Phase 1	29